Table 4 Demographic and clinical features of patients with two combined SNPs

n

78

55

8

2

61

64

13

5

H&Y stage^b

2.0 ± 1.5

2.0 ± 1.0

2.8 ± 0.5

2.50 ± 1.0

0.03*

2.5 ± 1.0

2.0 ± 1.0

2.0 ± 0.8

2.0 ± 1.5

0.12

Age onset (years)^a

60.7 ± 9.2

57.5 ± 9.5

56.8 ± 5.7

58.0 ± 5.7

0.03*

59.4 ± 9.6

58.6 ± 8.8

60.8 ± 10.9

60.8 ± 5.1

0.71

Disease duration (years)^b

6.0 ± 4.0

6.0 ± 6.0

8.5 ± 9.5

9.0 ± 4.0

0.02*

6.0 ± 5.5

6.0 ± 5.3

8.0 ± 8.5

4.0 ± 3.5

0.67

LED (mg)^a

386.2 ± 287.5

494.0 ± 360.7

692.4 ± 344.8

675.0 ± 35.4

0.01*

479.0 ± 401.5

431.8 ± 241.4

416.4 ± 342.2

448.8 ± 327.4

0.67

Wearing-off (yes, %)

18 (23.1)

19 (34.6)

5 (62.5)

1(50.0)

0.02*

20 (32.8)

17 (26. 6)

5 (38.5)

1 (20.0)

0.87

Dyskinesia (yes, %)

7 (9.0)

9 (16.4)

2 (25.0)

0

0.07

8 (13.1)

7 (10.9)

3 (23.1)

0

0.52

UPDRS Part I score^b

2.0 ± 3.0

3.0 ± 3.0

2.0 ± 3.5

3.0 ± 0.0

0.98

2.0 ± 4.0

2.0 ± 3.0

3.0 ± 3.0

3.0 ± 5.5

0.50

UPDRS Part II score^b

8.5 ± 9.0

8.0 ± 6.0

13.0 ± 7.8

13.5 ± 17.0

0.03*

8.0 ± 7.0

8.5 ± 7.0

9.0 ± 7.5

10.0 ± 13.0

0.77

UPDRS Part III score^a

25.9 ± 11.9

21.9 ± 11.7

31.0 ± 11.9

32.0 ± 21.2

0.08

25.1 ± 12.3

24.5 ± 12.2

26.2 ± 10.3

19.4 ± 14. 9

0.83

UPDRS Part IV score^b

3.0 ± 2.0

2.0 ± 3. 0

4.5 ± 4.0

4.0 ± 2.0

0.24

3.0 ± 3.5

2.0 ± 2.8

3.0 ± 2.0

2.0 ± 4.0

0.78

UPDRS total score^a

41.0 ± 17.4

36.4 ± 16.6

52.0 ± 19.7

52.5 ± 34.7

0.047*

40.5 ± 18.6

39.1 ± 17.2

44.1 ± 15.5

34.6 ± 20.4

0.86

NMS score^b

6.0 ± 6.0

6.0 ± 4.0

6.5 ± 10.8

6.5 ± 9.0

0.85

7.0 ± 6.5

6.0 ± 5.75

6.0 ± 6.0

9.0 ± 11.0

0.46

HAMA score^b

4.0 ± 6.0

5.0 ± 5.0

4.5 ± 13.3

3.0 ± 4.0

0.29

5.0 ± 6.0

4.0 ± 4.0

6.0 ± 6.0

8.0 ± 12.5

0.20

HAMD score^b

2.0 ± 5.0

4.0 ± 4.0

3.0 ± 6.5

2.0 ± 4.0

0.56

2.0 ± 6.5

3.0 ± 4.0

2.0 ± 2.0

7.0 ± 7.5

0.86

MMSE score^b

28.0 ± 3.0

28.0 ± 3.0

27.5 ± 3.0

26.5 ± 3.0

0.72

28.0 ± 3.0

28.0 ± 3.0

28.0 ± 3.0

29.0 ± 2.0

0.37